Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score

Table 1

Baseline characteristics of the patients in this study and in the original A.L.A.N. study.

	This study	Original A.L.A.N. exploratory cohort	Original A.L.A.N. validation cohort
	(n = 74)	(n = 123)	(n = 60)
Age, years (median, range)	65 (22–86)	67 (29–85)	64 (54–70)
Gender
Female	32 (43%)	65 (53%)	31 (52%)
Male	42 (57%)	58 (47%)	29 (48%)
Performance status
ECOG 0-1	69 (93%)	101 (82%)	50 (83%)
ECOG ≥2	5 (7%)	22 (18%)	10 (17%)
Primary tumour site
iCCA	49 (66%)	61 (50%)	17 (28%)
pCCA	11 (15%)	15 (12%)	18 (30%)
dCCA	3 (4%)	9 (7%)	19 (32%)
GBC	11 (15%)	38 (31%)	0
Unknown	0	0	13 (20%)
Cirrhosis among patients with iCCA
Yes	7 (14%)	5 (8%)	—
No	42 (86%)	56 (92%)	—
Disease status
Locally advanced	24 (32%)	15 (12%)	15 (25%)
Metastatic	50 (68%)	108 (88%)	45 (75%)
First-line chemotherapy
Gemcitabine and cisplatin	30 (40%)	71 (58%)	33 (55%)
Gemcitabine	16 (22%)	8 (6%)	13 (22%)
Others	28 (38%)	44 (36%)	14 (23%)
Combined agents
Yes	53 (72%)	110 (89%)	—
No	21 (28%)	13 (11%)	—
Second-line chemotherapy
Yes	23 (31%)	36 (29%)	24 (40%)
No	51 (69%)	87 (71%)	36 (60%)
Laboratory test (median, range)
ANC (cells/μl)	6012 (1867–15548)	5504 (1690–36230)	—
LMR	2.19 (0.80–66.83)	—	—
Albumin (g/dl)	3.5 (1.7–4.6)	3.7 (2.1–4.9)	—
NLR	4.87 (1.11–12.80)	—	—

ECOG: Eastern Cooperative Oncology Group; iCCA: intrahepatic cholangiocarcinoma; pCCA: perihilar cholangiocarcinoma; dCCA: distal cholangiocarcinoma; GBC: gallbladder cancer; ANC: actual neutrophil count; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio. Data for the A.L.A.N. cohorts are adapted from the original publication and presented for comparison [25]. Other chemotherapy regimens for our cohort were: gemcitabine and sorafenib (n = 12); capecitabine and oxaliplatin (n = 5); capecitabine (n = 3); gemcitabine and oxaliplatin (n = 2); fluorouracil and imantinib (n = 2); fluorouracil, folinic acid, and irinotecan (n = 1); cisplatin and fluorouracil (n = 1); irinotecan (n = 1); oxaliplatin (n = 1). As further treatment during the course of disease.